Agios Pharmaceuticals Company Profile (NASDAQ:AGIO)

About Agios Pharmaceuticals

Agios Pharmaceuticals logoAgios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs), which are a subset of orphan genetic metabolic diseases. Its cancer product candidates are AG-221 and AG-120, which targets mutated isocitrate dehydrogenase 2 and 1, or IDH2 and IDH1, respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2. The lead product candidate in its RGD programs, AG-348, targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. Its AG-221 is an orally available, selective, inhibitor of the mutated IDH2 protein indicated for the treatment of patients with cancers. Its AG-120 is an orally available, selective, inhibitor of the mutated isocitrate dehydrogenase (IDH1) protein for the treatment of patients with cancers. AG-881 is an orally available, selective, brain-penetrant, pan-IDH mutant inhibitor.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: AGIO
  • CUSIP:
Key Metrics:
  • Previous Close: $51.82
  • 50 Day Moving Average: $44.25
  • 200 Day Moving Average: $45.69
  • 52-Week Range: $33.50 - $81.77
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -10.08
  • P/E Growth: 0.00
  • Market Cap: $2.01B
  • Outstanding Shares: 38,046,000
  • Beta: 2.02
Profitability:
  • Net Margins: -320.33%
  • Return on Equity: -47.69%
  • Return on Assets: -35.12%
Debt:
  • Current Ratio: 7.20%
  • Quick Ratio: 7.20%
Additional Links:
Companies Related to Agios Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Agios Pharmaceuticals (NASDAQ:AGIO) (?)
Ratings Breakdown: 6 Hold Ratings, 5 Buy Ratings
Consensus Rating:Hold (Score: 2.45)
Consensus Price Target: $63.88 (20.93% upside)

Analysts' Ratings History for Agios Pharmaceuticals (NASDAQ:AGIO)
Show:
DateFirmActionRatingPrice TargetDetails
9/8/2016Canaccord GenuityReiterated RatingBuy$90.00View Rating Details
8/19/2016BTIG ResearchInitiated CoverageNeutralView Rating Details
8/10/2016Goldman Sachs Group Inc.Reiterated RatingNeutral$46.00View Rating Details
7/12/2016Credit Suisse Group AGReiterated RatingBuyView Rating Details
6/13/2016Janney Montgomery ScottReiterated RatingNeutral$52.00 -> $47.00View Rating Details
6/13/2016JPMorgan Chase & Co.UpgradeNeutral -> Overweight$50.00 -> $62.00View Rating Details
5/24/2016Cowen and CompanyReiterated RatingBuyView Rating Details
5/19/2016Leerink SwannReiterated RatingMarket Perform$56.00View Rating Details
5/18/2016SunTrust Banks Inc.Boost Price TargetBuy$57.00 -> $65.00View Rating Details
11/9/2015Roth CapitalLower Price TargetNeutral$114.00 -> $75.00View Rating Details
11/9/2015Oppenheimer Holdings Inc.Reiterated RatingHoldView Rating Details
7/22/2015Northland SecuritiesInitiated CoverageOutperform$132.00View Rating Details
7/2/2015DesjardinsUpgradeHold -> BuyView Rating Details
6/2/2015Citigroup Inc.Initiated CoverageNeutral$132.00View Rating Details
5/8/2015MLV & Co.Initiated CoverageBuy$130.00View Rating Details
(Data available from 10/1/2014 forward)

Earnings

Earnings History for Agios Pharmaceuticals (NASDAQ:AGIO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/3/2016        
8/4/2016Q216($0.48)($1.47)$39.62 million$6.98 millionViewListenView Earnings Details
5/5/2016Q116($0.79)($0.61)$20.94 million$31.30 millionViewListenView Earnings Details
2/18/2016Q415($0.50)($1.08)$28.78 million$6.22 millionViewListenView Earnings Details
11/5/2015Q315($0.89)($1.07)$17.21 million$5.80 millionViewListenView Earnings Details
8/6/2015Q215($0.46)($0.85)$25.75 million$13.20 millionViewListenView Earnings Details
5/7/2015Q115($0.92)($0.13)$10.86 million$34.20 millionViewListenView Earnings Details
2/17/2015Q414($0.58)($0.76)$10.94 million$14.64 millionViewListenView Earnings Details
11/7/2014Q314($0.53)$0.10$8.45 millionViewListenView Earnings Details
8/7/2014Q2($0.41)($0.54)$11.00 million$8.41 millionViewListenView Earnings Details
5/8/2014Q1($0.38)($0.39)ViewListenView Earnings Details
3/6/2014Q4($0.34)($0.40)$6.19 million$6.70 millionViewListenView Earnings Details
11/7/2013($0.28)($0.47)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Agios Pharmaceuticals (NASDAQ:AGIO)
Current Year EPS Consensus Estimate: $-4.8 EPS
Next Year EPS Consensus Estimate: $-5.24 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.56)($0.48)($0.52)
Q2 20163($1.33)($1.15)($1.23)
Q3 20163($1.42)($1.26)($1.32)
Q4 20163($1.49)($0.91)($1.25)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Agios Pharmaceuticals (NASDAQ:AGIO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Agios Pharmaceuticals (NASDAQ:AGIO)
Insider Ownership Percentage: 10.55%
Institutional Ownership Percentage: 81.59%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/28/2016Lewis Clayton Jr. CantleyDirectorSell627$54.00$33,858.00View SEC Filing  
9/27/2016Lewis Clayton Jr. CantleyDirectorSell627$54.15$33,952.05View SEC Filing  
9/20/2016Scott BillerInsiderSell5,000$50.00$250,000.00View SEC Filing  
8/30/2016Lewis Clayton Jr. CantleyDirectorSell627$36.81$23,079.87View SEC Filing  
8/29/2016Lewis Clayton Jr. CantleyDirectorSell627$37.81$23,706.87View SEC Filing  
7/26/2016Lewis Clayton Jr. CantleyDirectorSell2,504$42.80$107,171.20View SEC Filing  
7/25/2016Lewis Clayton Jr. CantleyDirectorSell627$41.85$26,239.95View SEC Filing  
6/28/2016Lewis Clayton Jr. CantleyDirectorSell2,504$41.88$104,867.52View SEC Filing  
6/27/2016Lewis Clayton Jr. CantleyDirectorSell627$40.37$25,311.99View SEC Filing  
6/8/2016Scott BillerInsiderSell27,500$65.00$1,787,500.00View SEC Filing  
5/26/2016Lewis Clayton Jr. CantleyDirectorSell2,504$51.69$129,431.76View SEC Filing  
4/26/2016Lewis Clayton Jr. CantleyDirectorSell2,504$53.44$133,813.76View SEC Filing  
4/25/2016Lewis Clayton Jr. CantleyDirectorSell627$55.00$34,485.00View SEC Filing  
3/30/2016Lewis Clayton Jr. CantleyDirectorSell2,504$37.19$93,123.76View SEC Filing  
2/26/2016Lewis Clayton Jr. CantleyDirectorSell2,504$37.90$94,901.60View SEC Filing  
1/29/2016Lewis Clayton Jr. CantleyDirectorSell2,504$42.93$107,496.72View SEC Filing  
12/29/2015Lewis Clayton Jr. CantleyDirectorSell10,664$64.93$692,413.52View SEC Filing  
12/15/2015John Duncan HiggonsCOOSell20,000$50.09$1,001,800.00View SEC Filing  
11/17/2015Lewis Clayton Jr. CantleyDirectorSell9,408$59.83$562,880.64View SEC Filing  
11/16/2015John Duncan HiggonsCOOSell20,000$61.51$1,230,200.00View SEC Filing  
11/2/2015Scott BillerinsiderSell5,500$77.12$424,160.00View SEC Filing  
10/23/2015Lewis Clayton Jr. CantleyDirectorSell9,704$61.16$593,496.64View SEC Filing  
10/15/2015John Duncan HiggonsCOOSell20,000$71.04$1,420,800.00View SEC Filing  
9/30/2015Scott BillerinsiderSell5,500$70.44$387,420.00View SEC Filing  
9/25/2015Lewis Clayton Jr. CantleyDirectorSell9,704$83.25$807,858.00View SEC Filing  
9/24/2015Glenn GoddardSVPSell6,000$85.97$515,820.00View SEC Filing  
9/15/2015John Duncan HiggonsCOOSell20,000$91.11$1,822,200.00View SEC Filing  
8/18/2015Lewis Clayton Jr. CantleyDirectorSell9,704$94.94$921,297.76View SEC Filing  
8/17/2015John Duncan HiggonsCOOSell20,000$92.24$1,844,800.00View SEC Filing  
7/23/2015Glenn GoddardSVPSell7,000$120.45$843,150.00View SEC Filing  
7/20/2015Scott BillerInsiderSell5,500$113.87$626,285.00View SEC Filing  
7/17/2015Glenn GoddardSVPSell13,000$113.71$1,478,230.00View SEC Filing  
7/16/2015John Duncan HiggonsCOOSell20,000$114.02$2,280,400.00View SEC Filing  
7/16/2015Lewis Clayton Jr. CantleyDirectorSell9,704$114.28$1,108,973.12View SEC Filing  
6/25/2015Lewis Clayton Jr. CantleyDirectorSell9,704$105.13$1,020,181.52View SEC Filing  
6/15/2015John Duncan HiggonsCOOSell7,000$105.23$736,610.00View SEC Filing  
6/8/2015Scott BillerInsiderSell5,500$121.85$670,175.00View SEC Filing  
6/1/2015Christopher BowdenInsiderSell5,000$120.67$603,350.00View SEC Filing  
6/1/2015David P SchenkeinCEOSell13,000$120.67$1,568,710.00View SEC Filing  
5/27/2015David P SchenkeinCEOSell8,929$120.05$1,071,926.45View SEC Filing  
5/27/2015Glenn GoddardSVPSell2,171$120.05$260,628.55View SEC Filing  
5/20/2015Lewis Clayton Jr. CantleyDirectorSell9,704$116.64$1,131,874.56View SEC Filing  
5/15/2015John Duncan HiggonsCOOSell7,417$112.89$837,305.13View SEC Filing  
5/12/2015David P SchenkeinCEOSell5,200$110.02$572,104.00View SEC Filing  
5/8/2015David P SchenkeinCEOSell3,900$101.32$395,148.00View SEC Filing  
5/7/2015Scott BillerInsiderSell5,500$96.32$529,760.00View SEC Filing  
4/24/2015Lewis Clayton Jr. CantleyDirectorSell9,704$105.15$1,020,375.60View SEC Filing  
4/15/2015John Duncan HiggonsCOOSell6,583$99.54$655,271.82View SEC Filing  
4/13/2015David P SchenkeinCEOSell3,900$100.03$390,117.00View SEC Filing  
4/8/2015Scott BillerInsiderSell5,500$97.64$537,020.00View SEC Filing  
4/1/2015David P SchenkeinCEOSell3,900$92.54$360,906.00View SEC Filing  
3/27/2015Lewis Clayton Jr. CantleyDirectorSell9,704$93.58$908,100.32View SEC Filing  
3/16/2015Glenn GoddardSVPSell10,000$106.24$1,062,400.00View SEC Filing  
3/16/2015John Duncan HiggonsCOOSell7,000$106.24$743,680.00View SEC Filing  
3/16/2015Scott BillerInsiderSell5,500$106.81$587,455.00View SEC Filing  
3/2/2015David P SchenkeinCEOSell7,800$107.05$834,990.00View SEC Filing  
2/13/2015David P SchenkeinCEOSell1,471$120.22$176,843.62View SEC Filing  
2/13/2015Glenn GoddardSVPSell1,316$120.31$158,327.96View SEC Filing  
2/11/2015Glenn GoddardSVPSell16,513$107.12$1,768,872.56View SEC Filing  
2/9/2015Glenn GoddardSVPSell15,000$105.81$1,587,150.00View SEC Filing  
2/2/2015David P SchenkeinCEOSell10,400$114.31$1,188,824.00View SEC Filing  
1/2/2015David P SchenkeinCEOSell13,000$110.08$1,431,040.00View SEC Filing  
1/2/2015John Duncan HiggonsCOOSell12,000$110.08$1,320,960.00View SEC Filing  
1/2/2015Scott BillerInsiderSell4,500$110.08$495,360.00View SEC Filing  
12/16/2014Celgene European Investment CoMajor ShareholderBuy228,645$110.75$25,322,433.75View SEC Filing  
12/16/2014John MaraganoreDirectorBuy1,806$110.75$200,014.50View SEC Filing  
12/1/2014David P SchenkeinCEOSell13,000$97.03$1,261,390.00View SEC Filing  
12/1/2014John Duncan HiggonsCOOSell12,000$97.03$1,164,360.00View SEC Filing  
12/1/2014Scott BillerInsiderSell4,500$97.03$436,635.00View SEC Filing  
11/3/2014Glenn GoddardSVPSell2,000$81.71$163,420.00View SEC Filing  
11/3/2014John Duncan HiggonsCOOSell13,000$81.71$1,062,230.00View SEC Filing  
11/3/2014Scott BillerInsiderSell4,500$81.71$367,695.00View SEC Filing  
10/1/2014Glenn GoddardSVPSell1,500$60.07$90,105.00View SEC Filing  
10/1/2014John Duncan HiggonsCOOSell13,000$60.07$780,910.00View SEC Filing  
10/1/2014Scott BillerInsiderSell4,500$60.07$270,315.00View SEC Filing  
9/26/2014David P SchenkeinCEOSell60,000$62.68$3,760,800.00View SEC Filing  
9/26/2014Glenn GoddardSVPSell17,500$56.53$989,275.00View SEC Filing  
9/19/2014Scott BillerInsiderSell37,996$50.45$1,916,898.20View SEC Filing  
9/2/2014Glenn GoddardSVPSell10,000$46.30$463,000.00View SEC Filing  
9/2/2014John Duncan HiggonsCOOSell13,000$46.30$601,900.00View SEC Filing  
9/2/2014Scott BillerInsiderSell4,500$46.30$208,350.00View SEC Filing  
8/26/2014John Duncan HiggonsCOOSell5,000$45.05$225,250.00View SEC Filing  
8/11/2014David P SchenkeinCEOSell4,530$40.17$181,970.10View SEC Filing  
7/1/2014David P SchenkeinCEOSell13,000$46.52$604,760.00View SEC Filing  
7/1/2014Glenn GoddardSVPSell3,500$46.52$162,820.00View SEC Filing  
7/1/2014John Duncan HiggonsCOOSell12,000$46.52$558,240.00View SEC Filing  
7/1/2014Scott BillerInsiderSell4,500$46.52$209,340.00View SEC Filing  
6/23/2014John MaraganoreDirectorBuy2,300$43.98$101,154.00View SEC Filing  
6/20/2014Scott BillerInsiderSell2,004$50.05$100,300.20View SEC Filing  
6/13/2014John Duncan HiggonsCOOSell5,000$45.27$226,350.00View SEC Filing  
6/3/2014John Duncan HiggonsCOOSell7,000$34.47$241,290.00View SEC Filing  
5/6/2014John Duncan HiggonsCOOSell5,000$45.73$228,650.00View SEC Filing  
5/1/2014Glenn GoddardSVPSell2,000$42.39$84,780.00View SEC Filing  
5/1/2014John Duncan HiggonsCOOSell7,000$42.39$296,730.00View SEC Filing  
5/1/2014Scott BillerInsiderSell4,500$42.39$190,755.00View SEC Filing  
4/29/2014Celgene European Investment Comajor shareholderBuy294,800$44.00$12,971,200.00View SEC Filing  
4/29/2014John MaraganoreDirectorBuy2,250$44.00$99,000.00View SEC Filing  
4/7/2014Glenn GoddardSVPSell2,000$45.17$90,340.00View SEC Filing  
4/7/2014John Duncan HiggonsCOOSell3,000$45.17$135,510.00View SEC Filing  
4/1/2014Glenn GoddardSVPSell4,000$38.08$152,320.00View SEC Filing  
4/1/2014John Duncan HiggonsCOOSell12,000$38.08$456,960.00View SEC Filing  
4/1/2014Scott BillerInsiderSell4,500$38.08$171,360.00View SEC Filing  
3/7/2014Glenn GoddardSVPSell17,468$42.11$735,577.48View SEC Filing  
3/7/2014John Duncan HiggonsCOOSell14,646$41.41$606,490.86View SEC Filing  
3/3/2014John Duncan HiggonsCOOSell8,000$29.85$238,800.00View SEC Filing  
3/3/2014Scott BillerInsiderSell6,000$29.85$179,100.00View SEC Filing  
2/10/2014Glenn GoddardSVPSell6,000$30.44$182,640.00View SEC Filing  
1/27/2014Glenn GoddardSVPSell7,000$26.29$184,030.00View SEC Filing  
1/21/2014Glenn GoddardSVPSell10,000$34.71$347,100.00View SEC Filing  
7/29/2013Celgene European Investment CoMajor ShareholderBuy708,333$18.00$12,749,994.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Agios Pharmaceuticals (NASDAQ:AGIO)
DateHeadline
seekingalpha.com logoAML Therapies Part 2: Agios And ImmunoGen - Seeking Alpha (NASDAQ:AGIO)
seekingalpha.com - September 29 at 8:08 AM
News IconLearn details of the Global thalassemia pipeline 2016 market therapeutics development research (NASDAQ:AGIO)
www.whatech.com - September 27 at 3:21 PM
investornewswire.com logoCan Shares Of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Hit $90? - Investor Newswire (NASDAQ:AGIO)
www.investornewswire.com - September 26 at 8:21 PM
4-traders.com logoAgios Pharmaceuticals : Announces Pricing of $150 Million Public Offering of Common Stock (NASDAQ:AGIO)
www.4-traders.com - September 26 at 3:20 PM
News IconWilmerHale Advises Agios Pharmaceuticals in $173M Public Offering and Full Exercise of Option to Purchase Additional Shares (NASDAQ:AGIO)
www.wilmerhale.com - September 23 at 8:10 AM
investornewswire.com logoCan Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Surprise Analysts This Quarter? - Investor Newswire (NASDAQ:AGIO)
www.investornewswire.com - September 22 at 3:20 PM
finance.yahoo.com logoAgios Announces Closing of Public Offering and Full Exercise of ... - Yahoo Finance (NASDAQ:AGIO)
finance.yahoo.com - September 21 at 4:01 PM
4-traders.com logoAgios Pharmaceuticals : Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares (NASDAQ:AGIO)
www.4-traders.com - September 21 at 10:22 AM
publicnow.com logoAgios Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares (NASDAQ:AGIO)
www.publicnow.com - September 21 at 10:22 AM
realistinvestor.com logoAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) Is Expected To Post EPS Of $-1.38 - RealistInvestor.com (NASDAQ:AGIO)
www.realistinvestor.com - September 18 at 8:08 AM
News IconAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) Sale Analysis - Newburgh Press (NASDAQ:AGIO)
newburghpress.com - September 16 at 3:22 PM
4-traders.com logoAGIOS PHARMACEUTICALS INC : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K) (NASDAQ:AGIO)
www.4-traders.com - September 16 at 12:02 PM
finance.yahoo.com logoFloor seen for Agios Pharmaceuticals (NASDAQ:AGIO)
finance.yahoo.com - September 16 at 12:02 PM
biz.yahoo.com logoAGIOS PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Sta (NASDAQ:AGIO)
biz.yahoo.com - September 15 at 8:32 PM
streetinsider.com logoAgios Pharma (AGIO) Prices 3.37M Share Common Stock Offering for Proceeds of ~$150M (NASDAQ:AGIO)
www.streetinsider.com - September 15 at 3:21 PM
News IconAgios Pharmaceuticals, Inc Pipeline Review, Market Share, Size and Clinical trial 2016 – 2020 (NASDAQ:AGIO)
www.medgadget.com - September 15 at 3:21 PM
finance.yahoo.com logo3:00 am Agios Pharma prices offering of 3,370,786 shares of common stock at $44.50 per share (NASDAQ:AGIO)
finance.yahoo.com - September 15 at 3:21 PM
investopedia.com logoAgios to Raise $150 million in Stock Offering (NASDAQ:AGIO)
www.investopedia.com - September 15 at 3:21 PM
News IconBiotech Stocks Worth a Closer Look: Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), Agios Pharmaceuticals, Inc ... - The Voice Registrar (NASDAQ:AGIO)
voiceregistrar.com - September 15 at 12:14 PM
News IconAgios Pharmaceuticals, Inc Pipeline Review, Market Share, Size ... - Medgadget (blog) (NASDAQ:AGIO)
www.medgadget.com - September 15 at 12:14 PM
streetinsider.com logoAgios Pharma (AGIO) Prices 3.37M Share Common Stock Offering for Proceeds of ~$150M - StreetInsider.com (NASDAQ:AGIO)
www.streetinsider.com - September 15 at 12:14 PM
marketwatch.com logoAgios Files for Secondary Offering (NASDAQ:AGIO)
www.marketwatch.com - September 14 at 8:38 PM
rttnews.com logoAgios Pharmaceuticals Inc. (AGIO) Is Falling After Offering Announcement (NASDAQ:AGIO)
www.rttnews.com - September 14 at 8:38 PM
smarteranalyst.com logoStock Update (NASDAQ:AGIO): Agios Pharmaceuticals Inc Announces Proposed Offering of Common Stock (NASDAQ:AGIO)
www.smarteranalyst.com - September 14 at 8:38 PM
finance.yahoo.com logoAgios Announces Pricing of $150 Million Public Offering of Common Stock (NASDAQ:AGIO)
finance.yahoo.com - September 14 at 8:38 PM
247wallst.com logoAgios Files for Secondary Offering - 24/7 Wall St. (NASDAQ:AGIO)
247wallst.com - September 14 at 3:21 PM
rttnews.com logoAgios Pharmaceuticals Inc. (AGIO) Is Falling After Offering Announcement - RTT News (NASDAQ:AGIO)
www.rttnews.com - September 14 at 3:21 PM
News IconStock Tracker: Earnings & Estimates for Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Frisco Fastball (NASDAQ:AGIO)
friscofastball.com - September 14 at 9:24 AM
smarteranalyst.com logoStock Update (NASDAQ:AGIO): Agios Pharmaceuticals Inc Announces Proposed Offering of Common Stock - Smarter Analyst (NASDAQ:AGIO)
www.smarteranalyst.com - September 14 at 9:24 AM
publicnow.com logoAgios Announces Proposed Offering of Common Stock (NASDAQ:AGIO)
www.publicnow.com - September 14 at 9:24 AM
News IconShares Lower Over the Past Quarter: Agios Pharmaceuticals, Inc ... - Post News (NASDAQ:AGIO)
www.kentuckypostnews.com - September 11 at 8:07 AM
News IconAgios Pharmaceuticals Inc. (NASDAQ: AGIO) stock reaffirmed at ... - BNB Daily (blog) (NASDAQ:AGIO)
www.baseball-news-blog.com - September 10 at 8:07 AM
smarteranalyst.com logoCanaccord Positive on Agios Pharmaceuticals Inc (AGIO) on Back of NDA Filing (NASDAQ:AGIO)
www.smarteranalyst.com - September 9 at 3:21 PM
schaeffersresearch.com logoDrug News Drives Agios Pharmaceuticals Inc (AGIO) Options Demand (NASDAQ:AGIO)
www.schaeffersresearch.com - September 9 at 3:21 PM
fool.com logoWhy Agios Pharmaceuticals Inc Stock Skyrocketed Today (NASDAQ:AGIO)
www.fool.com - September 9 at 3:21 PM
capitalcube.com logoAgios Pharmaceuticals, Inc. – Value Analysis (NASDAQ:AGIO) : September 9, 2016 (NASDAQ:AGIO)
www.capitalcube.com - September 9 at 3:21 PM
News IconPlacing Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Shares Under the Microscope - Post News (NASDAQ:AGIO)
www.kentuckypostnews.com - September 9 at 8:08 AM
News IconStock Buzz- Agios Pharmaceuticals, Inc.'s (AGIO) - Hot Stocks Point (NASDAQ:AGIO)
www.hotstockspoint.com - September 8 at 11:54 AM
News IconAgios Pharmaceuticals Inc. (NASDAQ:AGIO) reported business highlights and financial results - Inside Trade (NASDAQ:AGIO)
insidetrade.co - September 8 at 11:54 AM
News IconBiotech Stocks Worth a Closer Look: Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), BioCryst Pharmaceuticals, Inc ... - The Voice Registrar (NASDAQ:AGIO)
voiceregistrar.com - September 8 at 11:54 AM
finance.yahoo.com logoAgios' (AGIO) Partner Celgene to File for Enasidenib, Stock Up (NASDAQ:AGIO)
finance.yahoo.com - September 8 at 11:54 AM
News IconBlog Coverage Celgene Partner of Agios Pharma Plans NDA to Get FDA Approval for Blood Cancer Drug AG 221 (NASDAQ:AGIO)
news.investornetwork.com - September 8 at 11:54 AM
benzinga.com logoWednesday's Market Wrap: Major Averages Close Mixed - Benzinga (NASDAQ:AGIO)
www.benzinga.com - September 7 at 8:30 PM
News IconShares Gapping Up Before the Open: Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Post News (NASDAQ:AGIO)
www.kentuckypostnews.com - September 7 at 3:22 PM
marketexclusive.com logoBiotech Movers: Retrophin Inc (NASDAQ:RTRX) and Agios Pharmaceuticals Inc (NASDAQ:AGIO) - Market Exclusive (NASDAQ:AGIO)
marketexclusive.com - September 7 at 3:22 PM
fool.com logoWhy Agios Pharmaceuticals Inc Stock Skyrocketed Today - Motley Fool (NASDAQ:AGIO)
www.fool.com - September 7 at 3:22 PM
investors.com logoAgios Stock Soars As Partner Celgene Preps Drug Filing (NASDAQ:AGIO)
www.investors.com - September 7 at 3:22 PM
streetinsider.com logoAgios Pharma (AGIO) Announces Submission of AG-221 NDA to FDA by Celgene (CELG) (NASDAQ:AGIO)
www.streetinsider.com - September 7 at 12:19 PM
247wallst.com logoDid Agios Just Speed Up Its Business Plan by 2 Years? (NASDAQ:AGIO)
247wallst.com - September 7 at 12:19 PM
finance.yahoo.com logoAgios to Present at Morgan Stanley Global Healthcare Conference Tuesday ... (NASDAQ:AGIO)
finance.yahoo.com - September 6 at 3:21 PM

Social

Agios Pharmaceuticals (NASDAQ:AGIO) Chart for Saturday, October, 1, 2016


Last Updated on 10/1/2016 by MarketBeat.com Staff